Ryan J. Watts - Jun 16, 2023 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Jun 16, 2023
Transactions value $
-$1,536,000
Form type
4
Date filed
6/20/2023, 06:28 PM
Previous filing
Apr 24, 2023
Next filing
Aug 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Options Exercise $34K +50K +2.23% $0.68* 2.29M Jun 16, 2023 See footnote F1
transaction DNLI Common Stock Sale -$1.57M -50K -2.18% $31.40 2.24M Jun 16, 2023 See footnote F1, F2
holding DNLI Common Stock 188K Jun 16, 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNLI Stock Option (right to buy) Options Exercise $0 -50K -4.27% $0.00 1.12M Jun 16, 2023 Common Stock 50K $0.68 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F2 The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted February 10, 2023.
F3 Includes 188,437 RSUs.
F4 The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.